Background The effects of the sodium-glucose co-transporter 2 inhibitor empagliflozin on
renal and cardiovascular disease have not been tested in a dedicated population of people …

ABSTRACT In the EMPA-KIDNEY (The Study of Heart and Kidney Protection With
Empagliflozin) trial, empagliflozin reduced cardiorenal outcomes by 28%(hazard ratio 0.72; …

Summary Background The EMPA-KIDNEY trial showed that empagliflozin reduced the risk
of the primary composite outcome of kidney disease progression or cardiovascular death in …

Background Sodium–glucose co-transporter-2 (SGLT2) inhibitors reduce progression of
chronic kidney disease and the risk of cardiovascular morbidity and mortality in a wide range …

Background The effects of empagliflozin in patients with chronic kidney disease who are at
risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed …

Abstract Aims/Introduction In the EMPA‐REG OUTCOME® trial, empagliflozin added to
standard of care improved clinically relevant kidney outcomes by 39%, slowed progression …

Background: In EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial
in Type 2 Diabetes Mellitus Patients) empagliflozin significantly reduced the risk of …

In patients with type 2 diabetes mellitus (T2DM) and cardiovascular (CV) disease,
empagliflozin (EMPA) decreased progression of chronic kidney disease (CKD), likely via a …

Background Diabetes confers an increased risk of adverse cardiovascular and renal events.
In the EMPA-REG OUTCOME trial, empagliflozin, a sodium–glucose cotransporter 2 …

Background Empagliflozin slowed the progression of CKD in patients with type 2 diabetes
and cardiovascular disease in the EMPA-REG OUTCOME Trial. In a prespecified statistical …